Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Prognostic value of HER2-low status in breast cancer: A systematic review and...

Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )

Dostarlimab chemo combo for primary advanced or recurrent endometrial cancer

Prof Matthew Powell - Washington University School of Medicine, Missouri, USA

Dostarlimab chemo combo for primary advanced or recurrent endometrial cancer ( Prof Matthew Powell - Washington University School of Medicine, Missouri, USA )

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

mRCC: Atezolizumab after progression with prior ICI treatment no benefit and...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active...

Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL ( Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan )

Nine-weeks trastuzumab still effective compared with one year trastuzumab for...

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment...

Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer ( Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan )

NSIA and Nigeria to improve treatment for Nigerians through the building of new...

Aminu Umar-Sadiq - MD & CEO, Nigeria Sovereign Investment Authority (NSIA)

NSIA and Nigeria to improve treatment for Nigerians through the building of new cancer centres ( Aminu Umar-Sadiq - MD & CEO, Nigeria Sovereign Investment Authority (NSIA) )

NSIA and BVGH aim to improve patient outcomes and access to quality cancer care

Dr Tolulope Adewole - Program Lead, MedServe, Nigeria Sovereign Investment...

NSIA and BVGH aim to improve patient outcomes and access to quality cancer care ( Dr Tolulope Adewole - Program Lead, MedServe, Nigeria Sovereign Investment Authority (NSIA) )

Optimising cervical cancer care in Nigeria

Prof Don Dizon - Rhode Island Hospital, Rhode Island, USA

Optimising cervical cancer care in Nigeria ( Prof Don Dizon - Rhode Island Hospital, Rhode Island, USA )

Tackling low-volumes of clinical trials in Africa

Prof Ifeoma Okoye - University of Nigeria, Nsukka, Nigeria

Tackling low-volumes of clinical trials in Africa ( Prof Ifeoma Okoye - University of Nigeria, Nsukka, Nigeria )

More from ecancer